Immune cell kinetics and antibody response in COVID‐19 patients with low‐count monoclonal B‐cell lymphocytosis
Open Access
- 4 October 2023
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 98 (12) , 1909-1922
Abstract
Low‐count monoclonal B‐cell lymphocytosis (MBLlo) has been associated with an underlying immunodeficiency and has recently emerged as a new risk factor for severe COVID‐19. Here, we investigated the kinetics of immune cell and antibody responses in blood during COVID‐19 of MBLlo versus non‐MBL patients. For this study, we analyzed the kinetics of immune cells in blood of 336 COVID‐19 patients (74 MBLlo and 262 non‐MBL), who had not been vaccinated against SARS‐CoV‐2, over a period of 43 weeks since the onset of infection, using high‐sensitivity flow cytometry. Plasma levels of anti‐SARS‐CoV‐2 antibodies were measured in parallel by ELISA. Overall, early after the onset of symptoms, MBLlo COVID‐19 patients showed increased neutrophil, monocyte, and particularly, plasma cell (PC) counts, whereas eosinophil, dendritic cell, basophil, and lymphocyte counts were markedly decreased in blood of a variable percentage of samples, and with a tendency toward normal levels from week +5 of infection onward. Compared with non‐MBL patients, MBLlo COVID‐19 patients presented higher neutrophil counts, together with decreased pre‐GC B‐cell, dendritic cell, and innate‐like T‐cell counts. Higher PC levels, together with a delayed PC peak and greater plasma levels of anti‐SARS‐CoV‐2‐specific antibodies (at week +2 to week +4) were also observed in MBLlo patients. In summary, MBLlo COVID‐19 patients share immune profiles previously described for patients with severe SARS‐CoV‐2 infection, associated with a delayed but more pronounced PC and antibody humoral response once compared with non‐MBL patients.Keywords
Funding Information
- Centro de Investigación Biomédica en Red de Cáncer (CB16/12/00400)
- Consejería de Educación, Junta de Castilla y León (PR‐2019 487971, SA109P20)
- Instituto de Salud Carlos III (COV20/00386, FI20/00116, PI17/00399, PI22/00674)
- Interreg (0639‐IDIAL‐NET‐3‐3)
- Junta de Castilla y León (GRS‐COVID‐33/A/20)
This publication has 38 references indexed in Scilit:
- Age-associated distribution of normal B-cell and plasma cell subsets in peripheral bloodJournal of Allergy and Clinical Immunology, 2018
- Low-count monoclonal B-cell lymphocytosis persists after seven years of follow up and is associated with a poorer outcomeHaematologica, 2018
- Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myelomaLeukemia, 2017
- Monoclonal B‐cell lymphocytosis (MBL) with normal lymphocyte counts is associated with decreased numbers of normal circulating B‐cell subsetsAmerican Journal of Hematology, 2012
- Comparison of interlaboratory variation in absolute T‐cell counts by single‐platform and optimized dual‐platform methodsCytometry Part B: Clinical Cytometry, 2009
- Increased frequency (12%) of circulating chronic lymphocytic leukemia–like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approachBlood, 2009
- Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2008
- Diagnostic criteria for monoclonal B‐cell lymphocytosisBritish Journal of Haematology, 2005
- Monoclonal CD5+ and CD5- B-lymphocyte expansions are frequent in the peripheral blood of the elderlyBlood, 2004
- Monoclonal B lymphocytes with the characteristics of “indolent” chronic lymphocytic leukemia are present in 3.5% of adults with normal blood countsBlood, 2002